

ASTRAZENECA PLC  
Form 6-K  
May 13, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of May 2015  
Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES:

1. Identity of the issuer or the underlying issuer  
of existing shares to which voting rights are  
attached: ii

AstraZeneca PLC

Edgar Filing: ASTRAZENECA PLC - Form 6-K

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

The Capital Group Companies, Inc.

4. Full name of shareholder(s) (if different from 3.):iv

See Schedule A

5. Date of the transaction and date on which the threshold is crossed or reached: v

11 May 2015

6. Date on which issuer notified:

12 May 2015

7. Threshold(s) that is/are crossed or reached: vi, vii

Above 3%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares	Situation previous to the triggering transaction	Resulting situation after the triggering transaction			
		Number of Shares	Number of Voting Rights	Number of shares Direct	Number of voting rights Direct xi Indirect xii
Ordinary Shares (ISIN: GB0009895292)	32,100,333	32,100,333		32,139,533	2.544%
ADRs (ISIN: US0463531089)	5,767,760	5,767,760		5,768,891	0.457%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration date xiii	Exercise/Conversion Period xiv	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument	Exercise price	Expiration date xvii	Exercise/Conversion Period	Number of voting rights instrument refers to	% of voting rights xix, xx

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Conversion  
period xviii

Nominal

Delta

Total (A+B+C)

Number of voting rights

37,908,424

Percentage of voting rights

3.000%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

See Schedule A

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Martin Bennett, Assistant Company Secretary

15. Contact telephone number:

020 7604 8157

Schedule A

As of 11 May 2015

AstraZeneca PLC

	Number of Shares	Percent of Outstanding
The Capital Group Companies, Inc. ("CG") holdings	37,908,424	3.000%
Holdings by CG Management Companies and Funds:		
Capital Guardian Trust Company	5,439,762	0.431%
Capital International Limited	165,000	0.013%
Capital International Sàrl	153,792	0.012%
Capital International, Inc.	72,300	0.006%
Capital Research and Management Company	32,077,570	2.539%

SIGNATURES

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 13 May 2015

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary